Search

Displaying results 141 - 150 of 1795 in total
  1. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin … Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.

  2. Drug

    Ciprofloxacin

    go.drugbank.com/drugs/DB00537
    ApprovedInvestigational

    [L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]

    Products: CIPRO DENK 500MG FTA, CIPRO DENK 750MG FTA
  3. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [L2939]. … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label].

  4. Drug

    Meloxicam

    go.drugbank.com/drugs/DB00814
    ApprovedInvestigationalVet approved

    Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAI...

    Products: FRI-ART
  5. Drug

    Thalidomide

    go.drugbank.com/drugs/DB01041
    ApprovedInvestigationalWithdrawn

    A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thal...

  6. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] … [FDA Label, F4555, F4567, L6262] The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

  7. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … [FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.

    Mixtures: COTA-KBProducts: KETOCONAZOLE HRA, Ketoconazole Hra
  8. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    and the proportion of Fabry disease patients that could benefit from migalastat therapy, Amicus Therapeutics' brand name Galafold was approved using the Accelerated Approval pathway, under which the FDA

  9. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). … [A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease.

    Products: PLEON RA, AZULFIDINE RA
  10. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    Bovine thrombin however, is capable of causing fatal severe bleeding or thrombosis [FDA Label]. This thrombosis may result from the development of antibodies against bovine thrombin [FDA Label]. … Bleeding may result from the development of antibodies against bovine factor V [FDA Label].